Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• Tiotropium is a key treatment for chronic obstructive pulmonary disease (COPD).
• It is available via two inhaler devices: HandiHaler (18 μg) and Respimat Soft Mist Inhaler (5 μg).
• Previous studies indicated similar safety profiles between the two delivery methods.

Purpose of the Study:

• To conduct a comprehensive safety evaluation of tiotropium.
• To compare safety data from placebo-controlled trials using both HandiHaler and Respimat inhalers.
• To provide an updated safety assessment of tiotropium in COPD patients.

Main Methods:

• Pooled analysis of adverse event (AE) data from randomized, double-blind, placebo-controlled clinical trials.
• Included trials involved tiotropium HandiHaler (18 μg) and Respimat (5 μg) in COPD patients.
• Incidence rates and rate ratios (RRs) with 95% confidence intervals (CIs) were calculated.

Main Results:

• Analysis included 11,626 placebo and 12,929 tiotropium patient-years across 35 trials.
• Tiotropium significantly reduced the risk of AEs (RR 0.90) and SAEs (RR 0.94) versus placebo.
• A numerically lower risk of fatal AEs (FAEs) (RR 0.90) and cardiac AEs (RR 0.93) was observed with tiotropium.

Conclusions:

• Tiotropium, delivered via HandiHaler or Respimat, is associated with lower rates of AEs and SAEs compared to placebo.
• The safety profiles were consistent when analyzed separately for each inhaler device.
• Rates of FAEs were similar between tiotropium and placebo groups.